A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms VIVID-EAST; VIVID-EAST-DME
- Sponsors Bayer
- 06 Nov 2019 Results evaluating a cost-effective analysis to evaluate the long-term economic benefits of intravitreal aflibercept (IVT-AFL) versus macular laser and ranibizumab in the treatment of diabetic macular edema presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 29 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 07 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.